GSE185161
JAML is a novel immunotherapy target for tissue-resident memory T cells [scRNA-seq]
Tumor-infiltrating CD8+ T cells express high levels of the co-stimulatory molecule JAML, which can be exploited for cancer immunotherapy. Overall design: Single-cell RNA-seq was performed from CD45+JAML+ T cells isolatied from murine tumor (n = 3)